Clinical Trials Directory

Trials / Completed

CompletedNCT02258685

Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.

Status
Completed
Phase
Study type
Observational
Enrollment
93 (actual)
Sponsor
University of Colorado, Denver · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This study plans to learn more about immune responses in intestinal (gut) tissue in people with human immunodeficiency virus (HIV) infection. This study will determine whether change in the composition of gut bacteria in HIV infected individuals is related to a high prevalence of chronic gut inflammation and metabolic disease. The investigators will also investigate immune-modulatory properties of specific bacteria that correlate with disease both by characterizing which functional genes are selected for in their genomes and by stimulating immune cells isolated from blood and gut tissue with bacterial isolates. This work will establish whether gain/loss of bacterial drivers/suppressors of information in the gut contributes to metabolic disease in HIV-infected individuals.

Detailed description

This is a prospective cohort and cross-sectional case-control study. Study participation will last up to 2 months and 93 participants will be enrolled. Participants will be evaluated for lipodystrophy, asked to complete food \& gastrointestinal symptoms questionnaires and provide stool samples. A subset of participants will be asked to have a flexible sigmoidoscopy (mucosal biopsy). Cohort A will consist of 93 participants: Cohort A1: ART (Antiretroviral therapy) -treated HIV-infected individuals with lipodystrophy (n=35) Cohort A2: ART-treated HIV-infected individuals without lipodystrophy (n=18) Cohort A3: HIV-1 infected individuals naïve to ART (n=20) Cohort A4: HIV-1 seronegative individuals who are at a high risk for infection (n=20) Cohort B will be a selected subset of subjects from Cohort A: Cohort B1: ART-treated HIV-infected individuals with HIV-associated dysbiosis (n=10) Cohort B2: ART-treated HIV-infected individuals without HIV-associated dysbiosis (n=10)

Conditions

Timeline

Start date
2014-11-01
Primary completion
2018-11-01
Completion
2019-07-01
First posted
2014-10-07
Last updated
2019-12-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02258685. Inclusion in this directory is not an endorsement.